Adverse Event Preferred Term | Dose-Optimization Phase (Safety Population) | Crossover Phase (Randomized Population) | Â |
---|---|---|---|
 | LDX All Doses (N = 129) n (%) | LDX All Doses (n = 115) n (%) | Placebo (n = 115) n (%) |
Any adverse event | 110 (85.3) | 38 (33.0) | 22 (19.1) |
Affect lability | 13 (10.1) | 0 (0.0) | 1 (0.9) |
Decreased appetite | 61 (47.3) | 7 (6.1) | 1 (0.9) |
Headache | 22 (17.1) | 6 (5.2) | 2 (1.7) |
Insomnia | 35 (27.1) | 5 (4.3) | 0 (0.0) |
Irritability | 21 (16.3) | 1 (0.9) | 1 (0.9) |
Upper abdominal pain | 20 (15.5) | 2 (1.7) | 3 (2.6) |